Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Palazestrant by Olema Pharmaceuticals for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval
Palazestrant is under clinical development by Olema Pharmaceuticals and currently in Phase III for Human Epidermal Growth Factor Receptor 2...
Data Insights
Risk adjusted net present value: What is the current valuation of Olema Pharmaceuticals's Palazestrant?
Palazestrant is a small molecule commercialized by Olema Pharmaceuticals, with a leading Phase III program in Human Epidermal Growth Factor...